The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.

The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.

The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, etc. are defined as in claim 1.

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): ##STR00001##
wherein
Ar is a the partial structure (1) to the partial structure (5),
Q is a bivalent group selected from the group consisting of (Ia)-(If), and
B is a ring optionally having substituent(s),
or a salt thereof.

Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The invention relates to prodrug compounds of formula I: ##STR00001##
wherein R.sup.2, R.sup.3, R.sup.5, R.sup.7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.